علاج كثرة المنسجات من خلايا لانغرهانس في التهاب الأقنية الصفراوية المرتبط بـ LCH مع طفرة BRAF-V600E

References

1. For LCH-associated sclerosing cholangitis, the optimum therapy is unknown.
2. Due to poor outcomes with chemotherapy, targeted agents are preferable.
3. All patients with LCH should undergo BRAF-V600E mutational testing to aid in diagnosis and treatment.
4. For disease that is relapsed or refractory following chemotherapy, it is reasonable to consider an alternate chemotherapy agent or a kinase inhibitor based on patient-specific factors and drug availability.